# Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection

> **NCT03050307** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 234 (actual)

## Conditions studied

- Gastric Ulcer

## Interventions

- **DRUG:** TAK-438
- **DRUG:** Lansoprazole
- **DRUG:** TAK-438 Placebo
- **DRUG:** Lansoprazole Placebo
- **DRUG:** Bismuth-Containing Quadruple Therapy

## Key facts

- **NCT ID:** NCT03050307
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-17
- **Primary completion:** 2020-02-19
- **Final completion:** 2020-05-26
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050307, "Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03050307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*